Axis Bank received RBI approval for the re-appointment of Subrat Mohanty as Whole-Time Director (Executive Director). The appointment is for a three-year term effective from August 17, 2026, until August 16, 2029. This regulatory clearance follows the Board's earlier recommendation in January 2026.
Time Technoplast received PESO approval for India's first 250-litre Type IV composite hydrogen cylinders for buses and trucks. Prototype validation is expected within 90 days. This milestone strengthens the company's position in India's green hydrogen transition and sustainable mobility ecosystem, complementing its existing 150-litre hydrogen cylinder approvals.
The Orissa Minerals Development Company Regulatory Approval
Orissa Minerals Development Company Ltd received approval from the Government of Odisha for extending forest clearance for its Bhadrasahi Iron & Manganese Mining lease. The validity is extended until September 30, 2030, co-terminus with the mining lease period. This ensures continued operational stability for the company's mining activities.
BN Agrochem Limited (formerly BN Holdings Limited) received approval from the Competition Commission of India (CCI) for its scheme of amalgamation. The scheme involves merging A1 Agri Global, B.N. Agritech, and Salasar Balaji Overseas into BN Agrochem. This regulatory clearance is a significant milestone for completing the proposed corporate restructuring.
The Orissa Minerals Development Company Regulatory Approval
The Orissa Minerals Development Company Limited received approval from the Government of Odisha for the extension of forest clearance for its Bhadrasahi Iron & Manganese mining lease. The clearance is valid until September 30, 2030, aligning with the extended mining lease period. This provides long-term operational visibility for the company's mining activities.
OneSource Specialty Pharma's partner, Dr. Reddy's Laboratories, received Health Canada approval for its generic Semaglutide injection (Ozempic® generic). OneSource will serve as the CDMO partner providing scale-up and commercial manufacturing from its US-FDA approved Bengaluru facility. This regulatory milestone strengthens the partnership and leverages OneSource's specialty manufacturing capabilities.
Dr. Reddy's Laboratories received a Notice of Compliance from Health Canada for its generic Semaglutide Injection. This approval authorizes the company to commercialize and distribute the product in Canada, marking a significant milestone in its GLP-1 therapy portfolio. Launch preparations for 2 mg and 4 mg pens are currently underway.
OneSource Specialty Pharma Limited received an EU GMP Certificate for its Sterile Product Division in Bangalore from German authorities. The certification follows an October 2025 inspection and covers aseptic liquids, secondary packing, and quality control. This approval complements existing US-FDA, Health Canada, ANVISA, and TGA clearances, strengthening the facility's global sterile manufacturing capabilities.
PC Jeweller's step-down subsidiary, PCJ Mining SARL, was granted a one-year renewable license for semi-mechanized artisanal gold mining in Chad. This strategic move by the Ministry of Petroleum, Mining and Oil Geology enables the group to explore vertical integration opportunities in the precious metals sector.
One MobiKwik Systems Limited received RBI approval for its NBFC license application. The license enables the group to launch a new lending subsidiary, MobiKwik Financial Services Private Limited, to expand regulated credit offerings. This milestone strengthens MobiKwik's fintech capabilities and aims to improve lending margins by leveraging its 186 million+ customer base.
Zydus Lifesciences received DCGI approval to initiate Phase III clinical trials for Zintrodiazine, a novel anti-malarial candidate. Two trials involving 651 and 390 patients will evaluate efficacy against P. falciparum and P. vivax malaria in India. This marks a significant milestone in developing alternatives to current artemisinin-based therapies facing resistance.
Alembic Pharmaceuticals received USFDA final approval for Fingolimod Capsules, 0.5 mg, used for treating relapsing forms of multiple sclerosis. The product has an estimated annual market size of approximately ₹1363.0 Crore (US$ 145 million). This marks the company's 237th cumulative ANDA approval, strengthening its US generic portfolio.
Karur Vysya Bank received RBI approval to re-appoint Shri B Ramesh Babu as Managing Director & CEO for a third two-year term, effective July 29, 2026. This regulatory clearance ensures leadership continuity for the bank.
The Fertilisers and Chemicals Travancore Regulatory Approval
Fertilizers and Chemicals Travancore Limited (FACT) received Government approval to manufacture and sell DAP at its Udyogmandal, Kochi facility under the NBS Scheme. This permission allows the company to utilize existing capacity for DAP production and claim associated subsidies, subject to necessary compliance and regulatory conditions.
Mangal Credit and Fincorp Limited received a Corporate Agent (Composite) license from IRDAI, valid until April 2029. This approval allows the company to solicit insurance products to its customers, creating a new revenue stream through insurance distribution. The license was granted on April 24, 2026.
Go Digit General Insurance received 'no adverse observation' letters from BSE and NSE for its proposed merger with Go Digit Infoworks Services. This regulatory clearance allows the company to proceed with filing the scheme before the NCLT. The observation letters remain valid for six months from April 22, 2026.
Omaxe Limited's subsidiary, M/s Omaxe Garv Buildtech Private Limited, received a RERA Registration Certificate for its 'COMMERCIAL-3 BLOCK-3' project in Lucknow, Uttar Pradesh. The approval is valid until December 17, 2030. This regulatory milestone enables the company to commence sales, advertising, and transfers for the project, strengthening its operational presence in the region.
Saboo Sodium Chloro Limited received a critical Land Conversion Order for its 120-room luxury 5-star resort project in Jawai, Rajasthan. This regulatory milestone follows the Forest No Objection Certificate and enables the commencement of construction. The company has already appointed architects and civil contractors for the project.
Cipla's US subsidiary received final USFDA approval for the first AB-rated generic therapeutic equivalent of Ventolin HFA. The Albuterol Sulfate Inhalation Aerosol is expected to launch in H1 FY 2026-27, targeting a US market valued at $1.5 billion.
K.P. Energy Limited has been granted a Category V Inter-State Electricity Trading Licence by the CERC. This regulatory approval enables the company to trade electricity nationwide and participate in exchange-led markets. The licence strengthens the firm's commercial capabilities and supports its strategy of building an integrated renewable energy platform across India.
Bandhan Bank Limited has received RBI approval to appoint Mr. Debasish Panda as Part-time Chairman for a three-year term. Mr. Panda is a former IAS officer and former Chairman of IRDAI. The appointment is subject to final approval from the Bank's NRC and Board of Directors.
Sapphire Foods India Limited received approval from the Hon’ble Regional Director to shift its registered office from Maharashtra to Haryana. The order, dated April 21, 2026, follows the company's initial intimation in January 2026. This administrative move consolidates its corporate presence in the new state subject to requisite filings.
Sammaan Finserve Limited received 'no adverse observation' from BSE and 'no objection' from NSE for its scheme of arrangement with Sammaan Capital Limited. This regulatory clearance allows the company to file the scheme with the NCLT. The approvals remain valid for six months from April 22, 2026.
Sammaan Capital Limited received 'no adverse observation' from BSE and 'no objection' from NSE for its proposed Scheme of Arrangement with Sammaan Finserve Limited. These regulatory clearances enable the company to proceed with filing the scheme before the NCLT. The observation letters remain valid for six months from April 22, 2026.
Beta Drugs Limited achieved regulatory milestones in Azerbaijan and the Philippines. The company received generic drug approvals for two brands in the Philippines and successfully completed an Azerbaijan Ministry of Health inspection. These developments enhance access to CIS and Southeast Asian markets, supporting future export revenue growth.
Execution
Expected GMP approval in 1-2 months; further Philippines approvals in 6 months
Supriya Lifescience Ltd successfully completed a USFDA inspection at its Lote manufacturing facility. The inspection, conducted in February 2026, concluded with one minor observation and the receipt of an Establishment Inspection Report (EIR) indicating Voluntary Action Indicated (VAI) status. This confirms the facility's compliance with current Good Manufacturing Practice (cGMP) standards.
Kalyani Cast Tech Limited received approval for its 114-acre Non-Agricultural layout plan from the Gujarat Town Planning Authority. This facilitates essential utilities and statutory clearances for its Multimodal Logistics Park and Container Wagon Manufacturing Unit in Kutch. The approval enables the company to proceed with project operationalization as construction nears completion.
Beacon Trusteeship Limited received in-principle approval from IFSCA to provide Debenture Trustee Services from its proposed branch at GIFT City. The company has paid the required registration fees and will fulfill remaining regulatory conditions. This approval enables the company to expand its service offerings within the International Financial Services Centre framework.
Biocon Limited received Health Canada approval for its biosimilars Bosaya and Vevzuo, marking its entry into the Canadian denosumab market. The approval targets osteoporosis and cancer-related bone conditions, potentially benefiting over 2 million patients. This milestone strengthens Biocon's global biosimilars portfolio across immunology and oncology.
360 ONE WAM's step-down subsidiary, GAM, received in-principle approval from IFSCA to operate as a Fund Management Entity (Retail) in GIFT City. The company plans to infuse capital and obtain final registration to commence operations. This move expands the firm's global asset management footprint.
